Dianthus Therapeutics, Inc.
DNTH
Rankning i aktier
#3911
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aktiekurs
$75.21
Senast synkroniserad: 2026-10-19
Marknadsvärde
$4.21B
Förändring (1 dag)
4.33%
Förändring (1 år)
108.93%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Historik för aktiesplit för Dianthus Therapeutics, Inc. (DNTH)
Aktien Dianthus Therapeutics, Inc. (symbol: DNTH) har genomgått totalt 1 aktiesplitar.
Den senaste spliten skedde den Sep 12, 2023.
En DNTH-aktie köpt före Sep 12, 2023 motsvarar nu 0.0625 DNTH-aktier.
Den senaste spliten skedde den Sep 12, 2023.
En DNTH-aktie köpt före Sep 12, 2023 motsvarar nu 0.0625 DNTH-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| 2023-09-12 | 1:16 | x0.0625 | x0.0625 |
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
